Progyny (NASDAQ:PGNY) Issues Q3 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.500-0.520 for the period, compared to the consensus earnings per share estimate of 0.470. The company issued revenue guidance of $335.0 million-$345.0 million, compared to the consensus revenue estimate of $350.2 million. Progyny also updated its FY 2026 guidance to 2.040-2.100 EPS.

Analyst Ratings Changes

Several equities analysts recently weighed in on PGNY shares. Truist Financial raised their price objective on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. Leerink Partners set a $38.00 price target on Progyny in a research report on Wednesday, July 22nd. Barclays reaffirmed an “equal weight” rating and set a $34.00 price target (up from $27.00) on shares of Progyny in a research note on Tuesday, July 28th. Finally, Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.25.

Progyny Price Performance

NASDAQ:PGNY traded down $1.16 during trading hours on Thursday, reaching $30.21. 1,863,949 shares of the company traded hands, compared to its average volume of 996,015. The firm’s 50-day moving average is $29.02 and its 200-day moving average is $23.40. The stock has a market cap of $2.37 billion, a P/E ratio of 39.23, a P/E/G ratio of 2.49 and a beta of 1.01. Progyny has a 1-year low of $16.10 and a 1-year high of $33.06.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $348.63 million. During the same period in the previous year, the firm posted $0.19 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts predict that Progyny will post 1.19 earnings per share for the current year.

Progyny announced that its board has approved a share repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to buy up to 10.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Insider Transactions at Progyny

In other news, COO Melissa B. Cummings sold 9,578 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer owned 73,371 shares of the company’s stock, valued at $1,834,275. The trade was a 11.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the transaction, the director directly owned 19,772 shares in the company, valued at $521,783.08. The trade was a 27.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,916 shares of company stock worth $939,875 in the last ninety days. Company insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Progyny in the fourth quarter valued at $25,000. Canada Pension Plan Investment Board acquired a new stake in Progyny in the 2nd quarter worth about $77,000. Quarry LP boosted its stake in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Progyny by 203.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after buying an additional 4,708 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in Progyny in the 4th quarter valued at about $203,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.